Literature DB >> 12142309

Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study.

Tom Marshall1, Andrew Rouse.   

Abstract

OBJECTIVE: To develop a model to determine resource costs and health benefits of implementing guidelines for the prevention of cardiovascular disease in primary care.
DESIGN: Modelling of data from six strategies for prevention of cardiovascular disease. Strategies incorporated two ways of identifying patients for assessment: traditional (assessment of all adults) and novel (preselection of patients for assessment using a prior estimate of their risk of cardiovascular disease). Three treatment strategies were modelled in conjunction with each identification strategy.
SETTING: England.
SUBJECTS: Patients aged 30 to 74 eligible for primary prevention strategies for cardiovascular disease who were selected from a hypothetical population of 2000. MAIN OUTCOME MEASURES: Resource costs of assessing eligible adults, providing treatment and follow up to those eligible, and number of cardiovascular events this should prevent.
RESULTS: Novel strategies prevented more cardiovascular disease, at lower cost, than traditional strategies. Some treatment strategies prevent more cardiovascular disease with fewer resources than others. The findings were robust across a range of different assumptions about workload.
CONCLUSION: Preselecting patients for assessment makes better use of staff time than assessing all adults. Treating many patients with low cost drugs is more efficient than prescribing a few patients intensive antihypertensives and statins. Authors of guidelines should model workload implications and health benefits of following their recommendations.

Entities:  

Mesh:

Year:  2002        PMID: 12142309      PMCID: PMC117452          DOI: 10.1136/bmj.325.7357.197

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  16 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

2.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

3.  Meeting the National Service Framework for coronary heart disease: which patients have untreated high blood pressure?

Authors:  T Marshall; A Rouse
Journal:  Br J Gen Pract       Date:  2001-07       Impact factor: 5.386

4.  Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators.

Authors:  F Gueyffier; F Boutitie; J P Boissel; S Pocock; J Coope; J Cutler; T Ekbom; R Fagard; L Friedman; M Perry; R Prineas; E Schron
Journal:  Ann Intern Med       Date:  1997-05-15       Impact factor: 25.391

5.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors.

Authors:  G J Blauw; A M Lagaay; A H Smelt; R G Westendorp
Journal:  Stroke       Date:  1997-05       Impact factor: 7.914

6.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 7.  The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.

Authors:  P J Roderick; H C Wilkes; T W Meade
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

8.  Management of raised blood pressure in New Zealand: a discussion document.

Authors:  R Jackson; P Barham; J Bills; T Birch; L McLennan; S MacMahon; T Maling
Journal:  BMJ       Date:  1993-07-10

9.  Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B.

Authors:  S M Marcovina; V P Gaur; J J Albers
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

10.  Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

Authors:  T R Pedersen; J Kjekshus; K Berg; A G Olsson; L Wilhelmsen; H Wedel; K Pyörälä; T Miettinen; T Haghfelt; O Faergeman; G Thorgeirsson; B Jönsson; J S Schwartz
Journal:  Circulation       Date:  1996-05-15       Impact factor: 29.690

View more
  25 in total

1.  Primary prevention strategies for cardiovascular disease.

Authors:  Gill Tyerman; Peter Tyerman; Trefor J Roscoe
Journal:  BMJ       Date:  2002-10-26

2.  A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries.

Authors:  Anthony Rodgers
Journal:  BMJ       Date:  2003-06-28

3.  Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis.

Authors:  R J McManus; J Mant; A Roalfe; R A Oakes; S Bryan; H M Pattison; F D R Hobbs
Journal:  BMJ       Date:  2005-08-22

4.  Resource modelling: the missing piece of the HTA jigsaw?

Authors:  Praveen Thokala; Simon Dixon; Beate Jahn
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

5.  The use of cardiovascular risk factor information in practice databases: making the best of patient data.

Authors:  Tom Marshall
Journal:  Br J Gen Pract       Date:  2006-08       Impact factor: 5.386

6.  Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease.

Authors:  I Gemmell; R F Heller; P McElduff; K Payne; G Butler; R Edwards; M Roland; P Durrington
Journal:  J Epidemiol Community Health       Date:  2005-12       Impact factor: 3.710

7.  Predictors of patients' preferences for treatments to prevent heart disease.

Authors:  T Marshall; S Bryan; P Gill; S Greenfield; K Gutridge
Journal:  Heart       Date:  2006-05-18       Impact factor: 5.994

8.  Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study.

Authors:  Linn Getz; Johann A Sigurdsson; Irene Hetlevik; Anna Luise Kirkengen; Solfrid Romundstad; Jostein Holmen
Journal:  BMJ       Date:  2005-08-15

9.  Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study.

Authors:  Parinya Chamnan; Rebecca K Simmons; Kay-Tee Khaw; Nicholas J Wareham; Simon J Griffin
Journal:  BMJ       Date:  2010-04-23

10.  Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control.

Authors:  Linnea A Polgreen; Jayoung Han; Barry L Carter; Gail P Ardery; Christopher S Coffey; Elizabeth A Chrischilles; Paul A James
Journal:  Hypertension       Date:  2015-11-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.